Curated News
By: NewsRamp Editorial Staff
May 11, 2026
Kairos Pharma Sets Virtual Annual Meeting, Reports Going Concern
TLDR
- Kairos Pharma's ENV-105 targets CD105 to reverse drug resistance, offering a competitive edge in oncology by restoring standard therapy efficacy.
- Kairos Pharma holds virtual annual meeting June 29, 2026; 2025 annual report includes going concern note from auditors as per NYSE rules.
- Kairos Pharma's ENV-105 aims to overcome cancer drug resistance, potentially improving survival and quality of life for patients with unmet needs.
- Kairos Pharma's ENV-105 is in Phase 2 for prostate cancer and Phase 1 for lung cancer, targeting CD105 to reverse therapy resistance.
Impact - Why it Matters
The going concern disclosure by Kairos Pharma is crucial for investors as it signals potential financial uncertainty, which could affect the company's ability to continue operations. However, the company's ongoing clinical trials for ENV-105, targeting drug resistance in cancers like prostate and lung cancer, underscore the high-risk, high-reward nature of biotech investing. This news matters because it highlights the delicate balance between promising science and financial viability, directly impacting shareholder value and the future of novel cancer therapies.
Summary
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company based in Los Angeles, has announced that its annual meeting of shareholders will be held virtually on June 29, 2026, at 9 a.m. PDT. The company also disclosed that its 2025 annual report includes a going concern explanatory paragraph from its independent auditor, as required by NYSE American rules. Importantly, this disclosure does not amend any previously filed financial statements. Investors can find the full press release at https://ibn.fm/sQ0pm.
Kairos Pharma is focused on oncology therapeutics, leveraging structural biology to combat drug resistance and immune suppression in cancer. Its lead candidate, ENV-105, is an antibody targeting CD105, a protein linked to treatment resistance and disease relapse. ENV-105 aims to restore the effectiveness of standard therapies across multiple cancers. It is currently in a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. Notably, ENV-105 has not yet been approved by the FDA or any foreign regulator. For the latest updates on KAPA, visit the company’s newsroom at https://ibn.fm/KAPA.
This announcement was disseminated by TinyGems, a specialized communications platform focusing on innovative small-cap and mid-cap companies. TinyGems is part of the Dynamic Brand Portfolio @ IBN, offering services such as wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. TinyGems aims to cut through information overload, providing clients with unparalleled recognition and brand awareness. For more information, visit https://www.TinyGems.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma Sets Virtual Annual Meeting, Reports Going Concern
